Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Neoplasms;   Nasopharyngeal Diseases;   Head and Neck Neoplasm
Interventions:   Drug: Nimotuzumab;   Drug: Cisplatin
Sponsors:   Sun Yat-sen University;   Affiliated Cancer Hospital & Institute of Guangzhou Medical University;   Guangdong General Hospital;   First Affiliated Hospital, Sun Yat-Sen University
Recruiting

http://bit.ly/2Go1ge2